Apomorphine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Apomorphine" in English language version.

Last modified: 18:00:14, 1 October 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

9165nih.gov

5^th place

6951doi.org

2^nd place

1811books.google.com

3^rd place

1514semanticscholar.org

15^th place

8^th place

83hdl.handle.net

66^th place

34^th place

52fda.gov

470^th place

329^th place

51drugs.com

529^th place

550^th place

44worldcat.org

4^th place

33adsabs.harvard.edu

14^th place

9^th place

21amsterdamumc.nl

low place

21rug.nl

2,629^th place

1,971^st place

21patents.google.com

1,154^th place

606^th place

11tga.gov.au

4,353^rd place

2,806^th place

11springer.com

182^nd place

172^nd place

11unc.edu

1,577^th place

913^th place

11archive.org

6^th place

11realitystudio.org

low place

11apomorphine.info

low place

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

ui.adsabs.harvard.edu

Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K, et al. (May 2000). "Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes". Biochemical and Biophysical Research Communications. 272 (1): 18–22. Bibcode:2000BBRC..272...18O. doi:10.1006/bbrc.2000.2732. PMID 10872797.
Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A (April 2021). "Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs". Journal of Pharmaceutical Sciences. 110 (4): 1824–1833. Bibcode:2021JPhmS.110.1824I. doi:10.1016/j.xphs.2020.12.010. ISSN 0022-3549. PMID 33333142. S2CID 229317834.
Itin C, Komargodski R, Domb AJ, Hoffman A (September 2020). "Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study". Journal of Pharmaceutical Sciences. 109 (9): 2729–2734. Bibcode:2020JPhmS.109.2729I. doi:10.1016/j.xphs.2020.05.017. PMID 32497595. S2CID 219331493.

amsterdamumc.nl (Global: low place; English: low place)

pure.amsterdamumc.nl

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RM, Seppi K, et al. (August 2018). "International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease". Movement Disorders. 33 (8): 1248–1266. doi:10.1002/mds.27372. PMID 29570866.

apomorphine.info (Global: low place; English: low place)

"Apomorphine – A forgotten treatment for alcoholism". apomorphine.info. 21 June 2016. Retrieved 24 January 2018.

archive.org (Global: 6^th place; English: 6^th place)

Hare F (1912). On alcoholism; its clinical aspects and treatment. London: Churchill.

books.google.com (Global: 3^rd place; English: 3^rd place)

Lewitt P, Oertel WH (1999). Parkinson's Disease: The Treatment Options. CRC Press. p. 22. ISBN 978-1-85317-379-0.
Galvez-Jimenez M (2013). Scientific Basis for the Treatment of Parkinson's Disease (2nd ed.). CRC Press. p. 195. ISBN 978-0-203-33776-9.
Iversen L (2012). Biogenic Amine Receptors. Springer Science & Business Media. p. 238. ISBN 978-1-4684-8514-1.
Garattini S, Goldin A, Hawking F, Kopin IJ (1978). Advances in Pharmacology and Chemotherapy. Vol. 15. Academic Press. pp. 27, 93, 96. ISBN 978-0-08-058106-4.
Riviere JE, Papich MG (2009). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 318. ISBN 978-0-8138-2061-3.
Schapira AH, Olanow CW (2005). Principles of Treatment in Parkinson's Disease (illustrated ed.). Elsevier Health Sciences. p. 35. ISBN 978-0-7506-5428-9.
Porst H, Buvat J (2008). Standard Practice in Sexual Medicine. John Wiley & Sons. p. 77. ISBN 978-1-4051-7872-3.
Ishak WW (2017). The Textbook of Clinical Sexual Medicine. Springer. p. 388. ISBN 978-3-319-52539-6.
Bill RL (2016). Clinical Pharmacology and Therapeutics for Veterinary Technicians – E-Book. Elsevier Health Sciences. p. 94. ISBN 978-0-323-44402-6.
Khan SN, Hooser SB (2012). Common Toxicologic Issues in Small Animals, an Issue of Veterinary Clinics: Small Animal Practice – E-Book. Elsevier Health Sciences. p. 310. ISBN 978-1-4557-4325-4.
Peterson ME, Talcott PA (2006). Small Animal Toxicology. Elsevier Health Sciences. p. 131. ISBN 978-0-7216-0639-2.

doi.org (Global: 2^nd place; English: 2^nd place)

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
Albersen M, Mwamukonda KB, Shindel AW, Lue TF (January 2011). "Evaluation and treatment of erectile dysfunction". The Medical Clinics of North America. Urologic Issues for the Internist. 95 (1): 201–212. doi:10.1016/j.mcna.2010.08.016. PMID 21095423.
Guardia J, Casas M, Prat G, Trujols J, Segura L, Sánchez Turet M (October 2002). "The apomorphine test: a biological marker for heroin dependence disorder?". Addiction Biology. 7 (4): 421–426. doi:10.1080/1355621021000006206. PMID 14578019. S2CID 32386793.
Dent JY (1949). "Apomorphine Treatment of Addiction". British Journal of Addiction to Alcohol & Other Drugs. 46 (1): 15–28. doi:10.1111/j.1360-0443.1949.tb04502.x.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. (March 2017). "Parkinson disease". Nature Reviews. Disease Primers. 3 (1) 17013. doi:10.1038/nrdp.2017.13. PMID 28332488.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RM, Seppi K, et al. (August 2018). "International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease". Movement Disorders. 33 (8): 1248–1266. doi:10.1002/mds.27372. PMID 29570866.
Chen JJ, Obering C (November 2005). "A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease". Clinical Therapeutics. 27 (11): 1710–1724. doi:10.1016/j.clinthera.2005.11.016. PMID 16368444.
Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, et al. (September 2015). "Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations". Parkinsonism & Related Disorders. 21 (9): 1023–1030. doi:10.1016/j.parkreldis.2015.06.012. hdl:20.500.11940/8387. PMID 26189414.
Kassubek J, Jost WH, Schwarz J (October 2024). "Sublingual apomorphine in the treatment of Parkinson's disease". Journal of Neural Transmission. 131 (10). Vienna: 1209–1216. doi:10.1007/s00702-024-02777-z. PMID 38743091.
de Bie RM, Katzenschlager R, Swinnen BE, Peball M, Lim SY, Mestre TA, et al. (May 2025). "Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review". Movement Disorders. 40 (5): 776–794. doi:10.1002/mds.30162. PMC 12089898. PMID 40055961.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. (September 2018). "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. Neurology. 17 (9): 749–759. doi:10.1016/S1474-4422(18)30239-4. hdl:11370/7d4d28ce-d9f8-4751-a809-04f629fbd319. PMID 30055903.
Agbo F, Isaacson SH, Gil R, Chiu YY, Brantley SJ, Bhargava P, et al. (December 2021). "Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study". Neurology and Therapy. 10 (2): 693–709. doi:10.1007/s40120-021-00251-6. PMC 8571442. PMID 33991326.
Carbone F, Djamshidian A, Seppi K, Poewe W (September 2019). "Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations". CNS Drugs. 33 (9): 905–918. doi:10.1007/s40263-019-00661-z. PMC 6776563. PMID 31473980.
Isaacson SH, Dewey RB, Pahwa R, Kremens DE (2023). "How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature". Clinical Parkinsonism & Related Disorders. 8 100174. doi:10.1016/j.prdoa.2022.100174. PMC 9860403. PMID 36691604.
Youdim MB, Gassen M, Gross A, Mandel S, Grünblatt E (2000). "Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine". In Mizuno Y, Calne DB, Horowski R, Poewe W, Riederer P, Youdim MB (eds.). Advances in Research on Neurodegeneration, vol. 7. Seventh International Winter Conference on Neurodegeneration and Neuroinflammation. Karuizawa, Nagano, Japan. 20–22 January 1999. Journal of Neural Transmission. Supplementum. No. 58. Springer Science & Business Media. pp. 83–96. doi:10.1007/978-3-7091-6284-2_7. ISBN 978-3-211-83485-5. PMID 11128615.
Ptácek R, Kuzelová H, Stefano GB (September 2011). "Dopamine D₄ receptor gene DRD4 and its association with psychiatric disorders". Medical Science Monitor. 17 (9): RA215–RA220. doi:10.12659/MSM.881925. PMC 3560519. PMID 21873960.
Stacy M, Silver D (2008). "Apomorphine for the acute treatment of "off" episodes in Parkinson's disease". Parkinsonism & Related Disorders. 14 (2): 85–92. doi:10.1016/j.parkreldis.2007.07.016. PMID 18083605.
Rektorová I, Sedláčková S, Telečka S, Hlubočky A, Rektor I (2008). "Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson's disease by repetitive transcranial magnetic stimulation". International Journal of Biomedical Imaging. 2008 372125. doi:10.1155/2008/372125. PMC 2233877. PMID 18274665.
Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K, et al. (May 2000). "Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes". Biochemical and Biophysical Research Communications. 272 (1): 18–22. Bibcode:2000BBRC..272...18O. doi:10.1006/bbrc.2000.2732. PMID 10872797.
McGeary JE, Gurel V, Knopik VS, Spaulding J, McMichael J (October 2011). "Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain". Neuropeptides. 45 (5): 317–322. doi:10.1016/j.npep.2011.06.002. PMID 21820738. S2CID 38444849.
Heberlein A, Muschler M, Frieling H, Behr M, Eberlein C, Wilhelm J, et al. (May 2013). "Epigenetic down regulation of nerve growth factor during alcohol withdrawal". Addiction Biology. 18 (3): 508–510. doi:10.1111/j.1369-1600.2010.00307.x. PMID 21392176. S2CID 20317993.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D₂-like receptor and α₁/α₂-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT₁ and 5-HT₂, receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 815–822. doi:10.1124/jpet.102.039883. PMID 12388668. S2CID 19260572.
Hsieh GC, Hollingsworth PR, Martino B, Chang R, Terranova MA, O'Neill AB, et al. (January 2004). "Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine". The Journal of Pharmacology and Experimental Therapeutics. 308 (1): 330–338. doi:10.1124/jpet.103.057455. PMID 14569075. S2CID 7485959.
Chaudhuri KR, Clough C (February 1998). "Subcutaneous apomorphine in Parkinson's disease". BMJ. 316 (7132): 641. doi:10.1136/bmj.316.7132.641. PMC 1112674. PMID 9522772.
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, et al. (February 2020). "Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study". The Lancet. Neurology. 19 (2): 135–144. doi:10.1016/S1474-4422(19)30396-5. PMID 31818699.
Poklis JL, Mulder HA, Halquist MS, Wolf CE, Poklis A, Peace MR (July 2017). "The Blue Lotus Flower (Nymphea caerulea) Resin Used in a New Type of Electronic Cigarette, the Re-Buildable Dripping Atomizer". Journal of Psychoactive Drugs. 49 (3): 175–181. doi:10.1080/02791072.2017.1290304. PMC 5638439. PMID 28266899.
Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I (February 2004). "Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology". Journal of the Royal Society of Medicine. 97 (2): 84–85. doi:10.1177/014107680409700214. PMC 1079300. PMID 14749409.
Taba P, Lees A, Stern G (2013). "Erich Harnack (1852–1915) and a short history of apomorphine". European Neurology. 69 (6): 321–324. doi:10.1159/000346762. PMID 23549143.
"Apomorphine as a hypnotic". The Lancet. 155 (3998): 1083. April 1900. doi:10.1016/s0140-6736(01)70565-x.
Benes FM (January 2001). "Carlsson and the discovery of dopamine". Trends in Pharmacological Sciences. 22 (1): 46–47. doi:10.1016/S0165-6147(00)01607-2. PMID 11165672.
Ernst AM (May 1965). "Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS". Psychopharmacologia. 7 (6): 391–399. doi:10.1007/BF00402361. PMID 5831877. S2CID 7445311.
Halvorsen KA, Martensen-Larsen O (April 1978). "Apomorphine revived: fortified, prolonged, and improved therapeutical effect". The International Journal of the Addictions. 13 (3): 475–484. doi:10.3109/10826087809045262. PMID 352969.
Jensen SB, Christoffersen CB, Nørregaard A (December 1977). "Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study". The British Journal of Addiction to Alcohol and Other Drugs. 72 (4): 325–330. doi:10.1111/j.1360-0443.1977.tb00699.x. PMID 341937.
Schlatter EK, Lal S (June 1972). "Treatment of alcoholism with Dent's oral apomorphine method". Quarterly Journal of Studies on Alcohol. 33 (2): 430–436. doi:10.15288/qjsa.1972.33.430. PMID 5033142.
Lemere F, Voegtlin WL (June 1950). "An evaluation of the aversion treatment of alcoholism". Quarterly Journal of Studies on Alcohol. 11 (2): 199–204. doi:10.15288/qjsa.1950.11.199. PMID 15424345.
Dent JY (1 October 1934). "Apomorphine in the Treatment of Anxiety States, with Especial Reference to Alcoholism*". British Journal of Inebriety. 32 (2): 65–88. doi:10.1111/j.1360-0443.1934.tb05016.x. ISSN 1360-0443.
Morales Rosado JA, Cousin MA, Ebbert JO, Klee EW (December 2015). "A Critical Review of Repurposing Apomorphine for Smoking Cessation". Assay and Drug Development Technologies. 13 (10): 612–622. doi:10.1089/adt.2015.680. PMID 26690764.
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, et al. (September 2016). "Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease". Movement Disorders. 31 (9): 1366–1372. doi:10.1002/mds.26720. PMC 5053872. PMID 27430123.
Borkar N, Holm R, Yang M, Müllertz A, Mu H (November 2016). "In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs". International Journal of Pharmaceutics. 513 (1–2): 211–217. doi:10.1016/j.ijpharm.2016.09.024. PMID 27615708.
Netsomboon K, Partenhauser A, Rohrer J, Elli Sündermann N, Prüfert F, Suchaoin W, et al. (December 2016). "Preactivated thiomers for intranasal delivery of apomorphine: In vitro and in vivo evaluation". European Journal of Pharmaceutics and Biopharmaceutics. 109: 35–42. doi:10.1016/j.ejpb.2016.09.004. PMID 27615996.
Kapoor R, Turjanski N, Frankel J, Kleedorfer B, Lees A, Stern G, et al. (November 1990). "Intranasal apomorphine: a new treatment in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 53 (11): 1015. doi:10.1136/jnnp.53.11.1015. PMC 488291. PMID 2283516.
Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (March 1995). "Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application". European Journal of Drug Metabolism and Pharmacokinetics. 20 (1): 27–33. doi:10.1007/BF03192285. PMID 7588990. S2CID 7126130.
Ikechukwu Ugwoke M, Kaufmann G, Verbeke N, Kinget R (July 2000). "Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems". International Journal of Pharmaceutics. 202 (1–2): 125–131. doi:10.1016/S0378-5173(00)00434-8. PMID 10915935.
Grosset KA, Malek N, Morgan F, Grosset DG (September 2013). "Inhaled dry powder apomorphine (VR040) for 'off' periods in Parkinson's disease: an in-clinic double-blind dose ranging study". Acta Neurologica Scandinavica. 128 (3): 166–171. doi:10.1111/ane.12107. PMID 23527823. S2CID 22189634.
Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, et al. (August 2004). "Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease". Movement Disorders. 19 (8): 937–942. doi:10.1002/mds.20054. hdl:2318/41858. PMID 15300660. S2CID 28397399.
Van Laar T, Jansen EN, Essink AW, Rutten WJ, Neef C (August 1992). "Rectal apomorphine: a new treatment modality in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 55 (8): 737–738. doi:10.1136/jnnp.55.8.737-a. PMC 489221. PMID 1527553.
van Laar T, Jansen EN, Neef C, Danhof M, Roos RA (July 1995). "Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories". Movement Disorders. 10 (4): 433–439. doi:10.1002/mds.870100405. PMID 7565822. S2CID 30947265.
Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A (April 2021). "Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs". Journal of Pharmaceutical Sciences. 110 (4): 1824–1833. Bibcode:2021JPhmS.110.1824I. doi:10.1016/j.xphs.2020.12.010. ISSN 0022-3549. PMID 33333142. S2CID 229317834.
Itin C, Komargodski R, Domb AJ, Hoffman A (September 2020). "Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study". Journal of Pharmaceutical Sciences. 109 (9): 2729–2734. Bibcode:2020JPhmS.109.2729I. doi:10.1016/j.xphs.2020.05.017. PMID 32497595. S2CID 219331493.
Li GL, de Vries JJ, van Steeg TJ, van den Bussche H, Maas HJ, Reeuwijk HJ, et al. (January 2005). "Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment". Journal of Controlled Release. 101 (1–3): 199–208. doi:10.1016/j.jconrel.2004.09.011. PMID 15588905.

drugs.com (Global: 529^th place; English: 550^th place)

"Apomorphine Hydrochloride Monograph for Professionals". Drugs.com. Retrieved 26 February 2018.

fda.gov (Global: 470^th place; English: 329^th place)

accessdata.fda.gov

"ONAPGO- apomorphine hydrochloride injection, solution". United States Food & Drug Administration. Retrieved 1 April 2026.
"Apokyn (apomorphine hydrochloride injection), for subcutaneous use" (PDF). United States Food and Drug Administration. January 2025. Retrieved 21 April 2026.

hdl.handle.net (Global: 66^th place; English: 34^th place)

Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, et al. (September 2015). "Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations". Parkinsonism & Related Disorders. 21 (9): 1023–1030. doi:10.1016/j.parkreldis.2015.06.012. hdl:20.500.11940/8387. PMID 26189414.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. (September 2018). "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. Neurology. 17 (9): 749–759. doi:10.1016/S1474-4422(18)30239-4. hdl:11370/7d4d28ce-d9f8-4751-a809-04f629fbd319. PMID 30055903.
Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, et al. (August 2004). "Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease". Movement Disorders. 19 (8): 937–942. doi:10.1002/mds.20054. hdl:2318/41858. PMID 15300660. S2CID 28397399.

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
Albersen M, Mwamukonda KB, Shindel AW, Lue TF (January 2011). "Evaluation and treatment of erectile dysfunction". The Medical Clinics of North America. Urologic Issues for the Internist. 95 (1): 201–212. doi:10.1016/j.mcna.2010.08.016. PMID 21095423.
Guardia J, Casas M, Prat G, Trujols J, Segura L, Sánchez Turet M (October 2002). "The apomorphine test: a biological marker for heroin dependence disorder?". Addiction Biology. 7 (4): 421–426. doi:10.1080/1355621021000006206. PMID 14578019. S2CID 32386793.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. (March 2017). "Parkinson disease". Nature Reviews. Disease Primers. 3 (1) 17013. doi:10.1038/nrdp.2017.13. PMID 28332488.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RM, Seppi K, et al. (August 2018). "International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease". Movement Disorders. 33 (8): 1248–1266. doi:10.1002/mds.27372. PMID 29570866.
Chen JJ, Obering C (November 2005). "A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease". Clinical Therapeutics. 27 (11): 1710–1724. doi:10.1016/j.clinthera.2005.11.016. PMID 16368444.
Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, et al. (September 2015). "Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations". Parkinsonism & Related Disorders. 21 (9): 1023–1030. doi:10.1016/j.parkreldis.2015.06.012. hdl:20.500.11940/8387. PMID 26189414.
Kassubek J, Jost WH, Schwarz J (October 2024). "Sublingual apomorphine in the treatment of Parkinson's disease". Journal of Neural Transmission. 131 (10). Vienna: 1209–1216. doi:10.1007/s00702-024-02777-z. PMID 38743091.
de Bie RM, Katzenschlager R, Swinnen BE, Peball M, Lim SY, Mestre TA, et al. (May 2025). "Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review". Movement Disorders. 40 (5): 776–794. doi:10.1002/mds.30162. PMC 12089898. PMID 40055961.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. (September 2018). "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. Neurology. 17 (9): 749–759. doi:10.1016/S1474-4422(18)30239-4. hdl:11370/7d4d28ce-d9f8-4751-a809-04f629fbd319. PMID 30055903.
Agbo F, Isaacson SH, Gil R, Chiu YY, Brantley SJ, Bhargava P, et al. (December 2021). "Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study". Neurology and Therapy. 10 (2): 693–709. doi:10.1007/s40120-021-00251-6. PMC 8571442. PMID 33991326.
Carbone F, Djamshidian A, Seppi K, Poewe W (September 2019). "Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations". CNS Drugs. 33 (9): 905–918. doi:10.1007/s40263-019-00661-z. PMC 6776563. PMID 31473980.
Isaacson SH, Dewey RB, Pahwa R, Kremens DE (2023). "How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature". Clinical Parkinsonism & Related Disorders. 8 100174. doi:10.1016/j.prdoa.2022.100174. PMC 9860403. PMID 36691604.
Youdim MB, Gassen M, Gross A, Mandel S, Grünblatt E (2000). "Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine". In Mizuno Y, Calne DB, Horowski R, Poewe W, Riederer P, Youdim MB (eds.). Advances in Research on Neurodegeneration, vol. 7. Seventh International Winter Conference on Neurodegeneration and Neuroinflammation. Karuizawa, Nagano, Japan. 20–22 January 1999. Journal of Neural Transmission. Supplementum. No. 58. Springer Science & Business Media. pp. 83–96. doi:10.1007/978-3-7091-6284-2_7. ISBN 978-3-211-83485-5. PMID 11128615.
Ptácek R, Kuzelová H, Stefano GB (September 2011). "Dopamine D₄ receptor gene DRD4 and its association with psychiatric disorders". Medical Science Monitor. 17 (9): RA215–RA220. doi:10.12659/MSM.881925. PMC 3560519. PMID 21873960.
Stacy M, Silver D (2008). "Apomorphine for the acute treatment of "off" episodes in Parkinson's disease". Parkinsonism & Related Disorders. 14 (2): 85–92. doi:10.1016/j.parkreldis.2007.07.016. PMID 18083605.
Rektorová I, Sedláčková S, Telečka S, Hlubočky A, Rektor I (2008). "Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson's disease by repetitive transcranial magnetic stimulation". International Journal of Biomedical Imaging. 2008 372125. doi:10.1155/2008/372125. PMC 2233877. PMID 18274665.
Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K, et al. (May 2000). "Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes". Biochemical and Biophysical Research Communications. 272 (1): 18–22. Bibcode:2000BBRC..272...18O. doi:10.1006/bbrc.2000.2732. PMID 10872797.
McGeary JE, Gurel V, Knopik VS, Spaulding J, McMichael J (October 2011). "Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain". Neuropeptides. 45 (5): 317–322. doi:10.1016/j.npep.2011.06.002. PMID 21820738. S2CID 38444849.
Heberlein A, Muschler M, Frieling H, Behr M, Eberlein C, Wilhelm J, et al. (May 2013). "Epigenetic down regulation of nerve growth factor during alcohol withdrawal". Addiction Biology. 18 (3): 508–510. doi:10.1111/j.1369-1600.2010.00307.x. PMID 21392176. S2CID 20317993.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D₂-like receptor and α₁/α₂-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT₁ and 5-HT₂, receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 815–822. doi:10.1124/jpet.102.039883. PMID 12388668. S2CID 19260572.
Hsieh GC, Hollingsworth PR, Martino B, Chang R, Terranova MA, O'Neill AB, et al. (January 2004). "Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine". The Journal of Pharmacology and Experimental Therapeutics. 308 (1): 330–338. doi:10.1124/jpet.103.057455. PMID 14569075. S2CID 7485959.
Chaudhuri KR, Clough C (February 1998). "Subcutaneous apomorphine in Parkinson's disease". BMJ. 316 (7132): 641. doi:10.1136/bmj.316.7132.641. PMC 1112674. PMID 9522772.
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, et al. (February 2020). "Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study". The Lancet. Neurology. 19 (2): 135–144. doi:10.1016/S1474-4422(19)30396-5. PMID 31818699.
Poklis JL, Mulder HA, Halquist MS, Wolf CE, Poklis A, Peace MR (July 2017). "The Blue Lotus Flower (Nymphea caerulea) Resin Used in a New Type of Electronic Cigarette, the Re-Buildable Dripping Atomizer". Journal of Psychoactive Drugs. 49 (3): 175–181. doi:10.1080/02791072.2017.1290304. PMC 5638439. PMID 28266899.
Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I (February 2004). "Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology". Journal of the Royal Society of Medicine. 97 (2): 84–85. doi:10.1177/014107680409700214. PMC 1079300. PMID 14749409.
Taba P, Lees A, Stern G (2013). "Erich Harnack (1852–1915) and a short history of apomorphine". European Neurology. 69 (6): 321–324. doi:10.1159/000346762. PMID 23549143.
Benes FM (January 2001). "Carlsson and the discovery of dopamine". Trends in Pharmacological Sciences. 22 (1): 46–47. doi:10.1016/S0165-6147(00)01607-2. PMID 11165672.
Ernst AM (May 1965). "Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS". Psychopharmacologia. 7 (6): 391–399. doi:10.1007/BF00402361. PMID 5831877. S2CID 7445311.
Moynihan NH (August 1965). "The Treatment of Alcoholism in General Practice". The Practitioner. 195: 223–227. PMID 14328866.
Carlsson C, Johansson PR, Gullberg B (May 1977). "A double-blind cross-over study: apomorphine/placebo in chronic alcoholics". International Journal of Clinical Pharmacology and Biopharmacy. 15 (5): 211–213. PMID 326687.
Halvorsen KA, Martensen-Larsen O (April 1978). "Apomorphine revived: fortified, prolonged, and improved therapeutical effect". The International Journal of the Addictions. 13 (3): 475–484. doi:10.3109/10826087809045262. PMID 352969.
Jensen SB, Christoffersen CB, Nørregaard A (December 1977). "Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study". The British Journal of Addiction to Alcohol and Other Drugs. 72 (4): 325–330. doi:10.1111/j.1360-0443.1977.tb00699.x. PMID 341937.
Schlatter EK, Lal S (June 1972). "Treatment of alcoholism with Dent's oral apomorphine method". Quarterly Journal of Studies on Alcohol. 33 (2): 430–436. doi:10.15288/qjsa.1972.33.430. PMID 5033142.
Lemere F, Voegtlin WL (June 1950). "An evaluation of the aversion treatment of alcoholism". Quarterly Journal of Studies on Alcohol. 11 (2): 199–204. doi:10.15288/qjsa.1950.11.199. PMID 15424345.
De Morsier G, Feldmann H (1952). "[Apomorphine therapy of alcoholism; report of 500 cases]". Schweizer Archiv für Neurologie und Psychiatrie. Archives Suisses de Neurologie et de Psychiatrie. Archivio Svizzero di Neurologia e Psichiatria. 70 (2): 434–440. PMID 13075975.
Morales Rosado JA, Cousin MA, Ebbert JO, Klee EW (December 2015). "A Critical Review of Repurposing Apomorphine for Smoking Cessation". Assay and Drug Development Technologies. 13 (10): 612–622. doi:10.1089/adt.2015.680. PMID 26690764.
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, et al. (September 2016). "Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease". Movement Disorders. 31 (9): 1366–1372. doi:10.1002/mds.26720. PMC 5053872. PMID 27430123.
Borkar N, Holm R, Yang M, Müllertz A, Mu H (November 2016). "In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs". International Journal of Pharmaceutics. 513 (1–2): 211–217. doi:10.1016/j.ijpharm.2016.09.024. PMID 27615708.
Netsomboon K, Partenhauser A, Rohrer J, Elli Sündermann N, Prüfert F, Suchaoin W, et al. (December 2016). "Preactivated thiomers for intranasal delivery of apomorphine: In vitro and in vivo evaluation". European Journal of Pharmaceutics and Biopharmaceutics. 109: 35–42. doi:10.1016/j.ejpb.2016.09.004. PMID 27615996.
Kapoor R, Turjanski N, Frankel J, Kleedorfer B, Lees A, Stern G, et al. (November 1990). "Intranasal apomorphine: a new treatment in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 53 (11): 1015. doi:10.1136/jnnp.53.11.1015. PMC 488291. PMID 2283516.
Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (March 1995). "Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application". European Journal of Drug Metabolism and Pharmacokinetics. 20 (1): 27–33. doi:10.1007/BF03192285. PMID 7588990. S2CID 7126130.
Ikechukwu Ugwoke M, Kaufmann G, Verbeke N, Kinget R (July 2000). "Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems". International Journal of Pharmaceutics. 202 (1–2): 125–131. doi:10.1016/S0378-5173(00)00434-8. PMID 10915935.
Grosset KA, Malek N, Morgan F, Grosset DG (September 2013). "Inhaled dry powder apomorphine (VR040) for 'off' periods in Parkinson's disease: an in-clinic double-blind dose ranging study". Acta Neurologica Scandinavica. 128 (3): 166–171. doi:10.1111/ane.12107. PMID 23527823. S2CID 22189634.
Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, et al. (August 2004). "Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease". Movement Disorders. 19 (8): 937–942. doi:10.1002/mds.20054. hdl:2318/41858. PMID 15300660. S2CID 28397399.
Van Laar T, Jansen EN, Essink AW, Rutten WJ, Neef C (August 1992). "Rectal apomorphine: a new treatment modality in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 55 (8): 737–738. doi:10.1136/jnnp.55.8.737-a. PMC 489221. PMID 1527553.
van Laar T, Jansen EN, Neef C, Danhof M, Roos RA (July 1995). "Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories". Movement Disorders. 10 (4): 433–439. doi:10.1002/mds.870100405. PMID 7565822. S2CID 30947265.
Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A (April 2021). "Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs". Journal of Pharmaceutical Sciences. 110 (4): 1824–1833. Bibcode:2021JPhmS.110.1824I. doi:10.1016/j.xphs.2020.12.010. ISSN 0022-3549. PMID 33333142. S2CID 229317834.
Itin C, Komargodski R, Domb AJ, Hoffman A (September 2020). "Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study". Journal of Pharmaceutical Sciences. 109 (9): 2729–2734. Bibcode:2020JPhmS.109.2729I. doi:10.1016/j.xphs.2020.05.017. PMID 32497595. S2CID 219331493.
Li GL, de Vries JJ, van Steeg TJ, van den Bussche H, Maas HJ, Reeuwijk HJ, et al. (January 2005). "Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment". Journal of Controlled Release. 101 (1–3): 199–208. doi:10.1016/j.jconrel.2004.09.011. PMID 15588905.

ncbi.nlm.nih.gov

de Bie RM, Katzenschlager R, Swinnen BE, Peball M, Lim SY, Mestre TA, et al. (May 2025). "Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review". Movement Disorders. 40 (5): 776–794. doi:10.1002/mds.30162. PMC 12089898. PMID 40055961.
Agbo F, Isaacson SH, Gil R, Chiu YY, Brantley SJ, Bhargava P, et al. (December 2021). "Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study". Neurology and Therapy. 10 (2): 693–709. doi:10.1007/s40120-021-00251-6. PMC 8571442. PMID 33991326.
Carbone F, Djamshidian A, Seppi K, Poewe W (September 2019). "Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations". CNS Drugs. 33 (9): 905–918. doi:10.1007/s40263-019-00661-z. PMC 6776563. PMID 31473980.
Isaacson SH, Dewey RB, Pahwa R, Kremens DE (2023). "How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature". Clinical Parkinsonism & Related Disorders. 8 100174. doi:10.1016/j.prdoa.2022.100174. PMC 9860403. PMID 36691604.
Ptácek R, Kuzelová H, Stefano GB (September 2011). "Dopamine D₄ receptor gene DRD4 and its association with psychiatric disorders". Medical Science Monitor. 17 (9): RA215–RA220. doi:10.12659/MSM.881925. PMC 3560519. PMID 21873960.
Rektorová I, Sedláčková S, Telečka S, Hlubočky A, Rektor I (2008). "Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson's disease by repetitive transcranial magnetic stimulation". International Journal of Biomedical Imaging. 2008 372125. doi:10.1155/2008/372125. PMC 2233877. PMID 18274665.
Chaudhuri KR, Clough C (February 1998). "Subcutaneous apomorphine in Parkinson's disease". BMJ. 316 (7132): 641. doi:10.1136/bmj.316.7132.641. PMC 1112674. PMID 9522772.
Poklis JL, Mulder HA, Halquist MS, Wolf CE, Poklis A, Peace MR (July 2017). "The Blue Lotus Flower (Nymphea caerulea) Resin Used in a New Type of Electronic Cigarette, the Re-Buildable Dripping Atomizer". Journal of Psychoactive Drugs. 49 (3): 175–181. doi:10.1080/02791072.2017.1290304. PMC 5638439. PMID 28266899.
Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I (February 2004). "Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology". Journal of the Royal Society of Medicine. 97 (2): 84–85. doi:10.1177/014107680409700214. PMC 1079300. PMID 14749409.
Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, et al. (September 2016). "Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease". Movement Disorders. 31 (9): 1366–1372. doi:10.1002/mds.26720. PMC 5053872. PMID 27430123.
Kapoor R, Turjanski N, Frankel J, Kleedorfer B, Lees A, Stern G, et al. (November 1990). "Intranasal apomorphine: a new treatment in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 53 (11): 1015. doi:10.1136/jnnp.53.11.1015. PMC 488291. PMID 2283516.
Van Laar T, Jansen EN, Essink AW, Rutten WJ, Neef C (August 1992). "Rectal apomorphine: a new treatment modality in Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 55 (8): 737–738. doi:10.1136/jnnp.55.8.737-a. PMC 489221. PMID 1527553.

dailymed.nlm.nih.gov

"Onapgo- apomorphine hydrochloride injection, solution". DailyMed. 28 February 2025. Retrieved 2 April 2025.

pubchem.ncbi.nlm.nih.gov

PubChem. "Apomorphine". PubChem. U.S. National Library of Medicine. Retrieved 26 February 2018.

patents.google.com (Global: 1,154^th place; English: 606^th place)

EP 2007730, Gurusamy NU, "Process for making apomorphine and apocodeine", published 31 December 2008, assigned to Mallinckrodt Inc [Us] and Mallinckrodt, Inc.

realitystudio.org (Global: low place; English: low place)

Birmingham J (2 November 2009). "William Burroughs and the History of Heroin". RealityStudio.

rug.nl (Global: 2,629^th place; English: 1,971^st place)

research.rug.nl

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. (September 2018). "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial". The Lancet. Neurology. 17 (9): 749–759. doi:10.1016/S1474-4422(18)30239-4. hdl:11370/7d4d28ce-d9f8-4751-a809-04f629fbd319. PMID 30055903.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
Guardia J, Casas M, Prat G, Trujols J, Segura L, Sánchez Turet M (October 2002). "The apomorphine test: a biological marker for heroin dependence disorder?". Addiction Biology. 7 (4): 421–426. doi:10.1080/1355621021000006206. PMID 14578019. S2CID 32386793.
McGeary JE, Gurel V, Knopik VS, Spaulding J, McMichael J (October 2011). "Effects of nerve growth factor (NGF), fluoxetine, and amitriptyline on gene expression profiles in rat brain". Neuropeptides. 45 (5): 317–322. doi:10.1016/j.npep.2011.06.002. PMID 21820738. S2CID 38444849.
Heberlein A, Muschler M, Frieling H, Behr M, Eberlein C, Wilhelm J, et al. (May 2013). "Epigenetic down regulation of nerve growth factor during alcohol withdrawal". Addiction Biology. 18 (3): 508–510. doi:10.1111/j.1369-1600.2010.00307.x. PMID 21392176. S2CID 20317993.
Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D₂-like receptor and α₁/α₂-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT₁ and 5-HT₂, receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 815–822. doi:10.1124/jpet.102.039883. PMID 12388668. S2CID 19260572.
Hsieh GC, Hollingsworth PR, Martino B, Chang R, Terranova MA, O'Neill AB, et al. (January 2004). "Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine". The Journal of Pharmacology and Experimental Therapeutics. 308 (1): 330–338. doi:10.1124/jpet.103.057455. PMID 14569075. S2CID 7485959.
Ernst AM (May 1965). "Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS". Psychopharmacologia. 7 (6): 391–399. doi:10.1007/BF00402361. PMID 5831877. S2CID 7445311.
Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (March 1995). "Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application". European Journal of Drug Metabolism and Pharmacokinetics. 20 (1): 27–33. doi:10.1007/BF03192285. PMID 7588990. S2CID 7126130.
Grosset KA, Malek N, Morgan F, Grosset DG (September 2013). "Inhaled dry powder apomorphine (VR040) for 'off' periods in Parkinson's disease: an in-clinic double-blind dose ranging study". Acta Neurologica Scandinavica. 128 (3): 166–171. doi:10.1111/ane.12107. PMID 23527823. S2CID 22189634.
Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, et al. (August 2004). "Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease". Movement Disorders. 19 (8): 937–942. doi:10.1002/mds.20054. hdl:2318/41858. PMID 15300660. S2CID 28397399.
van Laar T, Jansen EN, Neef C, Danhof M, Roos RA (July 1995). "Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories". Movement Disorders. 10 (4): 433–439. doi:10.1002/mds.870100405. PMID 7565822. S2CID 30947265.
Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A (April 2021). "Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs". Journal of Pharmaceutical Sciences. 110 (4): 1824–1833. Bibcode:2021JPhmS.110.1824I. doi:10.1016/j.xphs.2020.12.010. ISSN 0022-3549. PMID 33333142. S2CID 229317834.
Itin C, Komargodski R, Domb AJ, Hoffman A (September 2020). "Controlled Delivery of Apomorphine Through Buccal Mucosa, Towards a Noninvasive Administration Method in Parkinson's Disease: A Preclinical Mechanistic Study". Journal of Pharmaceutical Sciences. 109 (9): 2729–2734. Bibcode:2020JPhmS.109.2729I. doi:10.1016/j.xphs.2020.05.017. PMID 32497595. S2CID 219331493.

springer.com (Global: 182^nd place; English: 172^nd place)

link.springer.com

Nakanishi E, Takahashi R (2022). "Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs". NeuroPsychopharmacotherapy. Springer, Cham. p. 3000. ISBN 978-3-030-62059-2. Retrieved 22 April 2026.

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

"Movapo Pod (Stada Pharmaceuticals Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 13 September 2024. Retrieved 15 September 2024.

unc.edu (Global: 1,577^th place; English: 913^th place)

pdsp.unc.edu

Roth BL, Driscol J (12 January 2011). "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 1 July 2014. Note: Values for humans are used. If there is more than one value listed for humans, their average is used.

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Ban TA (2008). Conditioning behavior and psychiatry. New Brunswick [N.J.]: AldineTransaction. ISBN 978-0-202-36235-9. OCLC 191318001.
Raikhel EA (2016). Governing habits: treating alcoholism in the post-Soviet clinic. Ithaca: Cornell University Press. ISBN 978-1-5017-0313-3. OCLC 965905763.
Dent JY (1 October 1934). "Apomorphine in the Treatment of Anxiety States, with Especial Reference to Alcoholism*". British Journal of Inebriety. 32 (2): 65–88. doi:10.1111/j.1360-0443.1934.tb05016.x. ISSN 1360-0443.
Itin C, Komargodski R, Barasch D, Domb AJ, Hoffman A (April 2021). "Prolonged Delivery of Apomorphine Through the Buccal Mucosa, Towards a Noninvasive Sustained Administration Method in Parkinson's Disease: In Vivo Investigations in Pigs". Journal of Pharmaceutical Sciences. 110 (4): 1824–1833. Bibcode:2021JPhmS.110.1824I. doi:10.1016/j.xphs.2020.12.010. ISSN 0022-3549. PMID 33333142. S2CID 229317834.

Apomorphine (English Wikipedia)

adsabs.harvard.edu (Global: 14th place; English: 9th place)

ui.adsabs.harvard.edu

amsterdamumc.nl (Global: low place; English: low place)

pure.amsterdamumc.nl

apomorphine.info (Global: low place; English: low place)

archive.org (Global: 6th place; English: 6th place)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

fda.gov (Global: 470th place; English: 329th place)

accessdata.fda.gov

hdl.handle.net (Global: 66th place; English: 34th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

patents.google.com (Global: 1,154th place; English: 606th place)

realitystudio.org (Global: low place; English: low place)

rug.nl (Global: 2,629th place; English: 1,971st place)

research.rug.nl

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

springer.com (Global: 182nd place; English: 172nd place)

link.springer.com

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

unc.edu (Global: 1,577th place; English: 913th place)

pdsp.unc.edu

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

adsabs.harvard.edu (Global: 14^th place; English: 9^th place)

archive.org (Global: 6^th place; English: 6^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

fda.gov (Global: 470^th place; English: 329^th place)

hdl.handle.net (Global: 66^th place; English: 34^th place)

nih.gov (Global: 5^th place; English: 5^th place)

patents.google.com (Global: 1,154^th place; English: 606^th place)

rug.nl (Global: 2,629^th place; English: 1,971^st place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

springer.com (Global: 182^nd place; English: 172^nd place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

unc.edu (Global: 1,577^th place; English: 913^th place)

worldcat.org (Global: 4^th place; English: 4^th place)